Osteoporosis represents a widespread disease, which affects about 75 million people in Europe, the United States, and Japan. Osteoporosis is characterized by a decrease of bone mass and an impairment of bone microarchitecture, resulting in a decreased bone strength and hence an increased fracture risk. In the United States, over 2 million incident fractures occur annually, causing costs of 16.9 billion dollars.
METHODS:
For the present study, fasting blood samples and femoral heads were obtained from 94 males and females who underwent elective hip arthroplasty. According to the National Institute of Health guidelines, the study was approved by the local Ethical Committee and was performed with informed consent of the subjects.
Fasting blood samples were used to measure serum concentrations of folate, vitamin B6, and vitamin B12. In addition, serum concentrations of the bone formation marker osteocalcin (OC) and the bone resorption marker tartrate-resistant acid phosphatase (TRAP) were determined. Bones were assessed by histomorphometry. According to the median B vitamin serum concentrations, results of the bone and serum analyses were grouped for individuals with high and low serum concentrations of folate, vitamin B6, and vitamin B12 (n=47 each).
All data are given as means±standard deviation (SD). The comparison between the experimental groups was performed by MannWhitney-U-test. A P value <0.05 was considered to indicate significant differences.
RESULTS SECTION:
The bone formation marker OC was found significantly higher in individuals with high serum B vitamins when compared to those with low serum B vitamins (folate: 24.0±12.6µg/L vs. 19.4±7.8 µg/L, P=0.04; vitamin B6: 23.9±12.2 µg/L vs. 19.6±8.5 µg/L, P=0.05; and vitamin B12: 24.2±12.4 µg/L vs. 19.1±7.8 µg/L, P=0.02). The serum concentration of the bone resorption marker TRAP was slightly but not significantly higher in individuals with high serum vitamin B12 (3.3±2.6 U/L vs. 2.7±0.7 U/L, P=0.12), while it did not differ between individuals with high and low serum folate and vitamin B6.
The histomorphometric analysis demonstrated a significantly lower trabecular thickness and percent trabecular area in individuals with low serum folate in comparison to individuals with high serum folate (Table  1 and Figure 1 ). Individuals with low serum vitamin B6 showed a significantly lower trabecular number when compared to individuals with high serum vitamin B6 (Table 1 and Figure 1 ). In contrast, we found no significant differences in the histomorphometric analysis between subjects with high and low serum vitamin B12 (Table 1) .
DISCUSSION:
To our knowledge, this study evaluated for the first time the association between serum B vitamins and bone properties in humans. Of interest, we found a relation between low serum folate and an impaired cancellous bone structure. Individuals with low serum vitamin B6 demonstrated a minor alteration of cancellous bone structure, while there was no association between low serum vitamin B12 and deteriorated cancellous bone structure.
The alterations of cancellous bone structure might be explained by an impaired osteoblast activity as indicated by low serum OC in subjects with low serum folate and vitamin B6. In spite of a vitamin B12-related elevation of serum OC, we found no association between serum vitamin B12 and trabecular bone architecture. These results might be explained by a concomitant vitamin B12-related elevation of ostoclast activity as indicated by the slightly elevated serum TRAP in subjects with high serum vitamin B12.
In general, it might be assumed that B vitamin deficiency affects cancellous bone structure by inducing hyperhomocysteinemia. On the other hand, B vitamins have also direct effects on bone metabolism. Therefore, B vitamin deficiency might be related to altered bone properties also independently of the homocysteine status.
In conclusion, this study provides to our knowledge the first evidence that low serum folate and vitamin B6 are related to an altered cancellous bone structure in humans. 
